The influence of corporate and political interests on models of illness in the evolution of the DSM

European Psychiatry

Volumn 26, Issue 3, 2011, Pages 194-200

  Pilecki, B C ^a   Clegg, J W ^b   McKay, D ^a  

^a FORDHAM UNIVERSITY   (United States)

^b JOHN JAY COLLEGE OF CRIMINAL JUSTICE   (United States)

Author keywords

DSM; History; Medical model

Indexed keywords

BIOTECHNOLOGICAL PROCEDURES; COGNITIVE THERAPY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DRUG INDUSTRY; HEALTH INSURANCE; HUMAN; MEDICAL RESEARCH; MENTAL DISEASE; MENTAL HEALTH; PRIORITY JOURNAL; PSYCHOANALYSIS; PSYCHOTHERAPY; SHORT SURVEY;

DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; HUMANS; MENTAL DISORDERS; POLICY; POLITICS;

EID: 79953297670     PISSN: 09249338     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eurpsy.2011.01.005     Document Type: Short Survey

References (43)

1. Abramowitz J.S., Taylor S., McKay D. Obsessive-compulsive disorder. Lancet 2009, 374:489-497.
2. American Psychiatric Association Practice guideline for the treatment of patients with obsessive-compulsive disorder 2007, Author, Arlington, VA.
3. Andrews G., Slade T. Agoraphobia without a history of panic disorder may be a part of the panic disorder syndrome. J Nerv Ment Dis 2002, 190:624-630.
4. Antonuccio D.O., Danton W.G., McClanahan T.M. Psychology in the prescription era: building a firewall between marketing and science. Am Psychol 2003, 58:1028-1043.
5. Balon R. Antidepressants in the treatment of premature ejaculation. J Sex Marital Ther 1996, 22:85-96.
6. Barlow D.H. Anxiety and its disorders 2002, Guilford, New York. 2nd ed.
7. Bekelman J.E., Li Y., Gross C.P. Scope and impact of financial conflicts of interest in biomedical research: a systematic review. JAMA 2003, 2003:454-465.
8. Berle D., Starcevic V., Hannan A., Milicevic D., Lamplugh C., Fenech P. Cognitive factors in panic disorder, agoraphobic avoidance, and agoraphobia. Behav Res Ther 2008, 46:282-291.
9. Bienvenu O.J., Onyike C.U., Stein M.B., Chen L., Samuels J., Nestadt G., et al. Agoraphobia in adults: incidence and longitudinal association with panic. Br J Psychiatry 2006, 188:432-438.
10. Blashfield R.K., Keely J.W., Burgess D.R. Classification. Oxford Textbook of Psychopathology 2009, 35-57. Oxford University Press, New York. 2nd ed. P. Blaneym, T. Millon (Eds.).
11. Boyd E.A., Bero L.A. Assessing faculty financial relationships with industry. JAMA 2000, 284:2209-2214.
12. Bremner J.D., Charney D.S. Neural circuits in fear and anxiety. Textbook of Anxiety Disorders 2010, 55-71. American Psychiatric Association, Washington, DC. 2nd ed. D.J. Stein, E. Hollander, B.O. Rothbaum (Eds.).
13. Brito A., Rodriguez M.A., Niaz M. A reconstruction of development of the periodic table based on history and philosophy of science and its implications for general chemistry textbooks. J Res Sci Teach 2004, 42:84-111.
14. Burns D.D., Eidelson R.J. Why are depression and anxiety correlated? A test of the tripartite model. J Consult Psychiatry 1998, 66:461-473.
15. Cosgrove L., Krimsky S., Vijayaraghavan M., Schneider L. Financial ties between DSM-IV panel Members and the pharmaceutical industry. Psychother Psychosom 2006, 75:154-160.
16. Deacon B.J., Lickel J.J. On the brain disease model of mental disorders. Behav Ther 2009, 32:113-116.
17. Follette W.C., Houts A.C. Models of scientific progress and the role of theory in taxonomy development: a case study of the DSM. J Consult Clin Psychol 1996, 64:1120-1132.
18. France C.M., Lysaker P.H., Robinson R.P. The " chemical imbalance" explanation for depression: origins, lay endorsement, and clinical implications. Prof Psychol Res Pract 2007, 38:411-420.
19. Galatzer-Levy I.R., Galatzer-Levy R.M. The revolution in psychiatric diagnosis: problems at the foundations. Perspect Biol Med 2007, 50:161-180.
20. Grob G.N. Origins of DSM-I: a study in appearance and reality. Am J Psychiatry 1991, 148:421-431.
21. Hayward C., Wilson K.A. Anxiety sensitivity: the missing piece to the agoraphobia - without - panic puzzle. Behav Modif 2007, 31:162-173.
22. Horwitz A. Creating mental illness 2002, University of Chicago Press, Chicago.
23. Jones K., Chen H.J., Jordan N., Boothroyd R.A., Ramoni-Perazzi J., Shern D.L. Examination of the effects of financial risk on the formal treatment costs for a medicaid population with psychiatric disorders. Med Care 2006, 44:320-327.
24. Kitcher P. The advancement of science: science without legend, objectivity without illusions 1993, Oxford University Press, New York.
25. Kupfer D.J., First M.B., Regier D.A. A research agenda for DSM-V 2002, American Psychiatric Association, Washington DC.
26. Mayes R, Horwitz A.V. DSM-III and the revolution in the classification of mental illness. J Hist Behav Sci 2005, 41:249-267.
27. Mayes R., Horwitz A.V. Correction to 'DSM-III and the revolution in the classification of mental illness'. J Hist Behav Sci 2007, 43:419.
28. McNally R.J. Panic disorder: a critical analysis 1994, Guilford, New York.
29. Mechanic D. Mental health and mental illness: definitions and perspectives. A handbook for the study of mental health 1999, Cambridge University Press, New York, NY. Social contexts, theories, and systems (Ed.).
30. Moynihan R., Cassels A. Selling sickness: how the world's biggest pharmaceutical companies are turning us all into patients 2005, Nation Books, New York.
31. National Institute for Health Clinical Excellence Obsessive-compulsive disorder 2006, British Psychological Society and the Royal College of Psychiatrists, London.
32. Nevels R.M., Dehon E.E., Alexander K., Gontkovsky S.T. Psychopharmacology of aggression in children and adolescents with primary neuropsychiatric disorders: a review of current and potentially promising treatment options. Exp Clin Psychopharmacol 2010, 18:184-201.
33. Nosen E., Woody S.R. Diagnostic assessment in research. Handbook of Research Methods in Abnormal and Clinical Psychology 2007, 109-124. Sage, Newbury Park, CA. D. McKay (Ed.).
34. Olatunji B.O., Wolitzky-Taylor K. Anxiety sensitivity and the anxiety disorders: a meta-analytic synthesis. Psychol Bull 2009, 135:974-999.
35. Olden K.W. The use of antidepressants in functional gastrointestinal disorders: new uses for old drugs. CNS Spectr 2005, 11:891-896.
36. Olfson M., Gorman J., Pardes H. Investing in mental health research. J Nerv Ment Dis 1996, 183:421-424.
37. Sharfstein S. Big pharma and American psychiatry: the good, the bad and the ugly. Psychiatr News 2005, 40:3-4.
38. Simpson H.B., Foa E.B., Liebowitz M.R., Ledley D.R., Huppert J.D., Cahill S., et al. A randomized-controlled trial of cognitive-behavioral therapy for augmenting pharmacotherapy in obsessive-compulsive disorder. Am J Psychiatry 2008, 165:621-630.
39. Spitzer R.L., Endicott J., Robins E. Research diagnostic criteria: rationale and reliability. Arch Gen Psychiatry 1978, 35:773-782.
40. Starcevic V. Opportunistic 'rediscovery' of mental disorders by the pharmaceutical industry. Psychother Psychosom 2002, 71:305-310.
41. Sylke A., Thiesen P., Mestel R., Koch U., Schulz H. Validity of routine clinical DSM-IV diagnoses (Axis I/II) in inpatients with mental disorders. Psychiatry Res 2009, 170:252-255.
42. Wittchen H., Nocon A., Beesdo K., Pine D.S., Hofler M., Lieb R., et al. Agoraphobia and panic: prospective-longitudinal relations suggest a rethinking of diagnostic concepts. Psychother Psychosom 2008, 77:147-157.
43. York University (2008). Big Pharma Spends More On Advertising Than Research And Development, Study Finds. ScienceDaily. Retrieved December 14, 2009, from http://www.sciencedaily.com/releases/2008/01/080105140107.htm.